Business Context and Reporting Period
PolyOne Corporation (now Avient Corp) filed this Form 8-K on August 5, 2004, to report the completion of the sale of its Elastomers & Performance Additives business. The transaction was executed with Excel Polymers LLC, an entity formed by an investor group led by Lion Chemical Capital, LLC and ACI Capital Co., Inc. The filing includes unaudited pro forma financial information reflecting the divestiture as if it had occurred prior to the periods presented.
Key Financial Metrics
Transaction Details
- Total Gross Proceeds: Approximately $120 million.
- Cash Consideration: $106 million.
- Non-Cash Consideration: $14 million promissory note from the buyer.
Pro Forma Balance Sheet (as of June 30, 2004)
| Item | Historical ($M) | Pro Forma ($M) |
|---|---|---|
| Total Assets | 1,975.0 | 1,839.8 |
| Total Liabilities | 1,595.9 | 1,460.4 |
| Long-term Debt | 753.7 | 674.9 |
| Shareholders' Equity | 379.1 | 379.4 |
Pro Forma Income Statement
| Period | Metric | Historical ($M) | Pro Forma ($M) |
|---|---|---|---|
| 12 Months Ended Dec 31, 2003 | Sales | 1,964.5 | 1,964.5 |
| Net Income (Loss) | (251.1) | (140.5) | |
| 6 Months Ended June 30, 2004 | Sales | 1,093.4 | 1,093.4 |
| Net Income (Loss) | 25.5 | 36.4 |
Note: The filing does not provide specific revenue or margin data for the sold business unit separately from the consolidated historical figures, though the pro forma adjustments eliminate the losses associated with discontinued operations.
Material Changes Versus Prior Period
The primary material change is the removal of the Elastomers & Performance Additives business from the consolidated financial statements. This divestiture significantly alters the company's historical profitability profile:
- Debt Reduction: Pro forma long-term debt decreased by $78.8 million due to the application of cash proceeds.
- Interest Expense: Pro forma interest expense is reduced by $8.0 million for the 12-month period and $4.0 million for the 6-month period.
- Profitability Improvement: The elimination of discontinued operations losses (which included significant impairment charges of $92.6 million in 2003 and $9.9 million in 2004) improved the pro forma net loss for 2003 by $110.6 million and increased pro forma net income for the first half of 2004 by $10.9 million.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the transaction details. The transaction was completed pursuant to an Asset Purchase Agreement dated June 28, 2004. The pro forma information assumes the sale occurred at the beginning of the periods presented. No unusual items other than the divestiture and associated impairment charges are highlighted in the text provided.
Investor Verification Checklist
- Verify the final closing date and any post-closing adjustments to the $120 million purchase price.
- Confirm the repayment schedule and interest rate terms of the $14 million promissory note.
- Review the specific allocation of the $106 million cash proceeds to ensure the debt reduction figures are accurate.
- Assess the impact of the divestiture on future revenue streams and customer concentration in the remaining business units.
- Check for any retained liabilities or contingent obligations related to the sold Elastomers & Performance Additives business.